Literature DB >> 28670363

Verapamil suppresses cardiac alternans and ventricular arrhythmias in acute myocardial ischemia via ryanodine receptor inhibition.

Yu-Lei Deng1, Jun-Yan Zhao2, Ji-Hua Yao1,3, Qiang Tang4, Le Zhang1, Hong-Lian Zhou1, Cun-Tai Zhang1, Jia-Gao Lv5, Xiao-Qing Quan1.   

Abstract

T-wave alternans (TWA) is a potent arrhythmia substrate under the conditions of acute myocardial ischemia. Abnormal intracellular calcium cycling contributes to the genesis of cardiac alternans. Ryanodine receptor (RyR) is a pivotal Ca2+ cycling protein central to Ca2+ signaling in the heart. Here, we investigated the potential role of RyR in cardiac alternans and ventricular arrhythmias in acute myocardial ischemia. Transmembrane action potentials were simultaneously recorded from epicardium and endocardium together with a transmural ECG and isometric contraction force in the arterially perfused left ventricular wedge preparations. Calcium alternans were induced by incremental frequency of field stimulation in rat ventricular myocytes. TWA, mechanical alternans and ventricular arrhythmias were reproducibly induced by rapid pacing in the acute ischemic wedge preparations. Compared with control group, calcium alternans ratio and spontaneous calcium release were increased in acute ischemic myocytes. Verapamil, a phenylalkylamine calcium channel blocker, can successfully abolish spontaneous calcium release, TWA, and ventricular arrhythmias. The inhibition effect of verapamil could be diminished by low concentration of ryanodine (10 nmol/L). However, nifedipine, a dihydropyridine calcium channel blocker, could not block TWA or arrhythmias. Moreover, verapamil, but not nifedipine, significantly decreased ROS production in ischemic myocytes. Collectively, our results indicate that verapamil can significantly inhibit the development of cardiac alternans and ventricular arrhythmias in acute myocardial ischemia, and the mechanism was related to the inhibition of RyR and the protective function to oxidative stress.

Entities:  

Keywords:  Verapamil; arrhythmias; cardiac alternans; myocardial ischemia; ryanodine receptor

Year:  2017        PMID: 28670363      PMCID: PMC5489875     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  54 in total

Review 1.  From pulsus to pulseless: the saga of cardiac alternans.

Authors:  James N Weiss; Alain Karma; Yohannes Shiferaw; Peng-Sheng Chen; Alan Garfinkel; Zhilin Qu
Journal:  Circ Res       Date:  2006-05-26       Impact factor: 17.367

2.  Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation.

Authors:  L Xu; J P Eu; G Meissner; J S Stamler
Journal:  Science       Date:  1998-01-09       Impact factor: 47.728

3.  Peroxisome proliferator-activated receptor γ (PPARγ) mediates the protective effect of quercetin against myocardial ischemia-reperfusion injury via suppressing the NF-κB pathway.

Authors:  Xinyu Liu; Zhangjie Yu; Xian Huang; Yi Gao; Xiuzhi Wang; Jianmin Gu; Song Xue
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

4.  Sevoflurane postconditioning improves myocardial mitochondrial respiratory function and reduces myocardial ischemia-reperfusion injury by up-regulating HIF-1.

Authors:  Long Yang; Peng Xie; Jianjiang Wu; Jin Yu; Tian Yu; Haiying Wang; Jiang Wang; Zhengyuan Xia; Hong Zheng
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

5.  Direct binding of verapamil to the ryanodine receptor channel of sarcoplasmic reticulum.

Authors:  H H Valdivia; C Valdivia; J Ma; R Coronado
Journal:  Biophys J       Date:  1990-08       Impact factor: 4.033

6.  Endocardial and epicardial repolarization alternans in human cardiomyopathy: evidence for spatiotemporal heterogeneity and correlation with body surface T-wave alternans.

Authors:  Raja J Selvaraj; Peter Picton; Kumaraswamy Nanthakumar; Susanna Mak; Vijay S Chauhan
Journal:  J Am Coll Cardiol       Date:  2007-01-23       Impact factor: 24.094

7.  Increasing gap junction coupling reduces transmural dispersion of repolarization and prevents torsade de pointes in rabbit LQT3 model.

Authors:  Xiao-Qing Quan; Rong Bai; Nian Liu; Bo-Di Chen; Cun-Tai Zhang
Journal:  J Cardiovasc Electrophysiol       Date:  2007-08-16

8.  Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study.

Authors:  Jorge A Salerno-Uriarte; Gaetano M De Ferrari; Catherine Klersy; Roberto F E Pedretti; Massimo Tritto; Luciano Sallusti; Luigi Libero; Giacinto Pettinati; Giulio Molon; Antonio Curnis; Eraldo Occhetta; Fabrizio Morandi; Paolo Ferrero; Francesco Accardi
Journal:  J Am Coll Cardiol       Date:  2007-10-22       Impact factor: 24.094

9.  Cellular basis for the electrocardiographic J wave.

Authors:  G X Yan; C Antzelevitch
Journal:  Circulation       Date:  1996-01-15       Impact factor: 29.690

10.  Anti-arrhythmic effect of verapamil is accompanied by preservation of cx43 protein in rat heart.

Authors:  Peng Zhou; Shu-Miao Zhang; Qiu-Lin Wang; Qi Wu; Mai Chen; Jian-Ming Pei
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

View more
  3 in total

1.  Simultaneous triple-parametric optical mapping of transmembrane potential, intracellular calcium and NADH for cardiac physiology assessment.

Authors:  Sharon A George; Zexu Lin; Igor R Efimov
Journal:  Commun Biol       Date:  2022-04-06

2.  Hydroxysafflor Yellow A Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Calcium Overload and Apoptosis.

Authors:  Jingxue Ye; Ruiying Wang; Min Wang; Jianhua Fu; Qiong Zhang; Guibo Sun; Xiaobo Sun
Journal:  Oxid Med Cell Longev       Date:  2021-05-21       Impact factor: 6.543

3.  Effects of artemisinin on ventricular arrhythmias in response to left ventricular afterload increase and microRNA expression profiles in Wistar rats.

Authors:  Xue Xu; Qiang Zhang; Huanqiu Song; Zhuo Ao; Xiang Li; Cheng Cheng; Maojing Shi; Fengying Fu; Chengtao Sun; Yuansheng Liu; Dong Han
Journal:  PeerJ       Date:  2018-12-20       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.